Close relatives of MERS-CoV in bats use ACE2 as their functional receptors.

Qing Xiong1 Lei Cao2 Chengbao Ma1 M Alejandra Tortorici3 Chen Liu1 Junyu Si1 Peng Liu1 Mengxue Gu1 Alexandra C Walls3,4 Chunli Wang1 Lulu Shi1 Fei Tong1 Meiling Huang1 Jing Li1 Chufeng Zhao1 Chao Shen1 Yu Chen1 Huabin Zhao5 Ke Lan1 Davide Corti6 David Veesler7,8 Xiangxi Wang9,10 Huan Yan11
Affiliations 11 institutions
  1. State Key Laboratory of Virology, Institute for Vaccine Research and Modern Virology Research Center, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
  2. CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  3. Department of Biochemistry, University of Washington, Seattle, WA, USA.
  4. Howard Hughes Medical Institute, Seattle, WA, USA.
  5. Department of Ecology, Tibetan Centre for Ecology and Conservation at WHU-TU, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China.
  6. Humabs BioMed SA, subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  7. Department of Biochemistry, University of Washington, Seattle, WA, USA. [email protected].
  8. Howard Hughes Medical Institute, Seattle, WA, USA. [email protected].
  9. CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. [email protected].
  10. University of Chinese Academy of Sciences, Beijing, China. [email protected].
  11. State Key Laboratory of Virology, Institute for Vaccine Research and Modern Virology Research Center, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China. [email protected].

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) and several bat coronaviruses use dipeptidyl peptidase-4 (DPP4) as an entry receptor1-4. However, the receptor for NeoCoV-the closest known MERS-CoV relative found in bats-remains unclear5. Here, using a pseudotype virus entry assay, we found that NeoCoV and its close relative, PDF-2180, can efficiently bind to and use specific bat angiotensin-converting enzyme 2 (ACE2) orthologues and, less favourably, human ACE2 as entry receptors through their receptor-binding domains (RBDs) on the spike (S) proteins. Cryo-electron microscopy analysis revealed an RBD-ACE2 binding interface involving protein-glycan interactions, distinct from those of other known ACE2-using coronaviruses. We identified residues 337-342 of human ACE2 as a molecular determinant restricting NeoCoV entry, whereas a NeoCoV S pseudotyped virus containing a T510F RBD mutation efficiently entered cells expressing human ACE2. Although polyclonal SARS-CoV-2 antibodies or MERS-CoV RBD-specific nanobodies did not cross-neutralize NeoCoV or PDF-2180, an ACE2-specific antibody and two broadly neutralizing betacoronavirus antibodies efficiently inhibited these two pseudotyped viruses. We describe MERS-CoV-related viruses that use ACE2 as an entry receptor, underscoring a promiscuity of receptor use and a potential zoonotic threat.

Supporting text Virus Host Location
Angiotensin-Converting Enzyme 2 177 Chiroptera 371 Middle East Respiratory Syndrome Coronavirus 68 Receptors, Virus 204 Virus Internalization 100 Animals 1948 Cryoelectron Microscopy 37 Dipeptidyl Peptidase 4 32 Humans 1440 Protein Binding 193 Spike Glycoprotein, Coronavirus 274 Viral Zoonoses 65 ACE2 protein, human 87

Evidence records

4 total
Functional Mechanism
4 records · 2 evidence types
Evidence type
3 records
OVE6573
Key finding

NeoCoV uses bat ACE2 orthologues and, less efficiently, human ACE2 as entry receptors through its spike RBD.

Virus
Host
Location
Not specified
Supporting text

we found that NeoCoV and its close relative, PDF-2180, can efficiently bind to and use specific bat angiotensin-converting enzyme 2 (ACE2) orthologues and, less favourably, human ACE2 as entry receptors through their receptor-binding domains (RBDs) on the spike (S) proteins.

Method
pseudotype virus entry assay | binding assay
Receptors
bat ACE2 | human ACE2
OVE6574
Key finding

PDF-2180 uses bat ACE2 orthologues and, less efficiently, human ACE2 as entry receptors through its spike RBD.

Virus
Host
Location
Not specified
Supporting text

we found that NeoCoV and its close relative, PDF-2180, can efficiently bind to and use specific bat angiotensin-converting enzyme 2 (ACE2) orthologues and, less favourably, human ACE2 as entry receptors through their receptor-binding domains (RBDs) on the spike (S) proteins.

Method
pseudotype virus entry assay | binding assay
Receptors
bat ACE2 | human ACE2
OVE6575
Key finding

Cryo-electron microscopy showed that NeoCoV RBD binds ACE2 through a unique protein–glycan interface distinct from other ACE2-using coronaviruses.

Virus
Host
Not specified
Location
Not specified
Supporting text

Cryo-electron microscopy analysis revealed an RBD-ACE2 binding interface involving protein-glycan interactions, distinct from those of other known ACE2-using coronaviruses.

Method
cryo-electron microscopy
Receptors
ACE2
Host factors
glycan
Evidence type
1 records
OVE6576
Key finding

A T510F mutation in the NeoCoV spike receptor-binding domain enables efficient entry via human ACE2, overcoming restriction imposed by human ACE2 residues 337–342.

Virus
Host
Not specified
Location
Not specified
Supporting text

We identified residues 337-342 of human ACE2 as a molecular determinant restricting NeoCoV entry, whereas a NeoCoV S pseudotyped virus containing a T510F RBD mutation efficiently entered cells expressing human ACE2.

Genes or proteins
Spike | RBD | ACE2
Receptors
ACE2
Host factors
residues 337–342 of human ACE2
Mutations
T510F
Mechanism types
receptor binding | receptor usage | host entry | host-range expansion